Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., . . . Gillison, M. L. (2018). Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol.
Citação norma ChicagoFerris, Robert L., et al. "Nivolumab Vs Investigator’s Choice in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: 2-year Long-term Survival Update of CheckMate 141 With Analyses By Tumor PD-L1 Expression." Oral Oncol 2018.
MLA citiranjeFerris, Robert L., et al. "Nivolumab Vs Investigator’s Choice in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: 2-year Long-term Survival Update of CheckMate 141 With Analyses By Tumor PD-L1 Expression." Oral Oncol 2018.